Endocan Is an Independent Predictor of Heart Failure-Related Mortality and Hospitalizations in Patients with Chronic Stable Heart Failure

Table 3

Univariate and multivariate predictors of HF-related mortality and hospitalization requiring inotropic support.

	Univariate HR (95% CI)		Multivariate HR (95% CI)
Age (per 1 year increase)	0.979 (0.842-1.012)	0.289	0.993 (0.949-1.039)	0.761
Gender (male vs. female)	1.462 (0.710-3.012)	0.303	1.184 (0.478-2.936)	0.715
Etiology (ischemic vs. nonischemic)	1.615 (1.094-2.387)	0.016	1.445 (0.955-2.189)	0.082
LVEF(per 1% increase)	1.032 (1.001-1.062)	0.040	1.011 (0.978-1.045)	0.506
NYHA class	3.419 (1.877-6.231)	0.001	2.825 (1.299-6.144)	0.009
Log NT-proBNP	5.016 (2.587-9.725)	<0.001	2.207 (1.002-4.861)	0.049
6 MW (per 1 meter increase)	0.997 (0.995-0.999)	0.001	0.997 (0.995-1.000)	0.032
Endocan levels (per 1 ng/mL increase)	1.518 (1.269-1.816)	<0.001	1.471 (1.183-1.829)	0.001

HR: hazard ratio; CI: confidence interval; LVEF: left ventricle ejection fraction; NYHA class: New York Heart Association class; 6MWT: 6-minute walking test; log NT-proBNP: logarithmic value of N-terminal pro-b-type natriuretic peptide.